share_log

Roth MKM Maintains Buy on Mind Medicine, Maintains $36 Price Target

Benzinga ·  Jul 24 23:21  · Ratings

Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment